TY - JOUR
T1 - New evidence on the management of Lewy body dementia
AU - Taylor, John Paul
AU - McKeith, Ian G.
AU - Burn, David J.
AU - Boeve, Brad F.
AU - Weintraub, Daniel
AU - Bamford, Claire
AU - Allan, Louise M.
AU - Thomas, Alan J.
AU - O'Brien, John T.
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/2
Y1 - 2020/2
N2 - Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.
AB - Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.
UR - http://www.scopus.com/inward/record.url?scp=85078506717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078506717&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(19)30153-X
DO - 10.1016/S1474-4422(19)30153-X
M3 - Review article
C2 - 31519472
AN - SCOPUS:85078506717
SN - 1474-4422
VL - 19
SP - 157
EP - 169
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 2
ER -